15-valent HPV Vaccine Currently in Phase II Clinical Trial Stage
December 4, 2025
Source: drugdu
41
Securities Daily Online - On December 2, Chengda Biotech responded to investor inquiries on the interactive platform, stating that the company's under-construction Biotech Product R&D and Production Base Project is planned in two phases: Phase I includes facilities such as a production workshop for the 15-valent HPV vaccine, while Phase II consists of standardized biopharmaceutical factory buildings, which will effectively support the industrialization of ongoing R&D projects. Currently, the 15-valent HPV vaccine is in the Phase II clinical trial stage. The vaccine's R&D, approval process, and project construction are influenced by multiple factors and carry certain uncertainties. The company will promptly disclose any latest developments in accordance with relevant regulations.
Reference：https://chat.deepseek.com/a/chat/s/0e718e8d-8f9c-4483-a333-6db4b824d280
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
